Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00215501 · ClinicalTrials.gov registry record · Phase 1
Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies
A Phase 1 study of Solid Tumor, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 3
- Study locations
NCT00215501: Completed Phase 1 study of Solid Tumor, sponsored by Dana-Farber Cancer Institute.
NCT00215501 is a Phase 1 study of Solid Tumor that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 54 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00215501, a Phase 1 study of Solid Tumor, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with unresectable, advanced solid tumors.
Conditions Studied
Interventions
- DRUG Capecitabine
- DRUG Cisplatin
- DRUG 5-Fluorouracil (5-FU)
- DRUG Irinotecan
Study Locations (3)
Massachusetts
- Massachusetts General Hospital - Boston
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2001-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
What the finished NCT00215501 record still lists
NCT00215501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 54 participants, a relatively small participant target, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which Capecitabine is the first listed.
NCT00215501 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00215501 about?
NCT00215501 is a clinical study titled "Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies". The purpose of this study is to test the safety of irinotecan and cisplatin in combination with either capecitabine or continuous infusion 5-fluorouracil and to see what effects (good and bad) these have on patients with unresectable, advanced solid tumors.
What is the current status of trial NCT00215501?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2001-11. Estimated completion is 2008-09.
What conditions does trial NCT00215501 study?
This clinical trial studies the following conditions: Solid Tumor.
What interventions are being tested in trial NCT00215501?
The interventions under investigation include: Capecitabine (DRUG), Cisplatin (DRUG), 5-Fluorouracil (5-FU) (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT00215501?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00215501 being conducted?
This trial has 3 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00215501's enrollment target sits among peer trials
54 117th of 196 higher than 78 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01269853 · 54 participants · Phase 1
Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA
- NCT02390752 · 54 participants · Phase 1
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
- NCT02991248 · 54 participants · NA
Improve Dynamic Lateral Balance of Humans With SCI
- NCT02993900 · 54 participants · NA
Image-Guided Gynecologic Brachytherapy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia